Ultra-low doses could bring costly cancer treatments to more patients in poorer countries
Topic: healthRegion: globalUpdated: i1 outletsSources: 1Spectrum: Center Only⏱ 4 min read⚠ 3d+ old
Story Summary
SITUATION
Researchers found that an ultra-low dose of nivolumab helped patients in India live longer. This approach could provide a more affordable cancer treatment option in resource-limited countries (per statnews.com).
Coveragetap to expand ▾Spectrum: Center Only🌍Other: 1
Political Spectrum
Position is inferred from coverage mix.
i1 outlets · Center
Left
Center
Right
Left: 0
Center: 1
Right: 0
Geography Coverage
Distribution of where coverage is coming from.
i1 unique outlets · Dominant: Global
KEY FACTS
- A lower-cost immunotherapy approach could extend survival for patients with advanced head and neck squamous cell carcinoma in resource-limited countries, according to re
HISTORICAL CONTEXT
The ongoing global health crisis, exacerbated by the COVID-19 pandemic, has significantly impacted healthcare systems worldwide, particularly in low- and middle-income countries. Since the onset of the pandemic in late 2019, many nations have struggled with resource allocation, leading to increased challenges in providing essential cancer treatments.
As of 2023, the World Health Organization reported that cancer care had been severely disrupted, with many patients facing delays in diagnosis and treatment due to overwhelmed healthcare facilities.
Brief
Recent research indicates that ultra-low doses of nivolumab, an immune checkpoint inhibitor, could significantly improve cancer treatment accessibility in poorer countries, particularly India.
In a phase 3 trial, patients with advanced head and neck squamous cell carcinoma who received this low-dose treatment experienced longer survival rates compared to those receiving standard chemotherapy.
The trial, conducted in India, highlights the pressing need for affordable cancer therapies in regions where high treatment costs often preclude access to life-saving medications. Nivolumab, while effective, is typically expensive, making it largely unavailable in resource-limited settings.
The ultra-low-dose regimen, known as TMC-I, costs approximately $230 a month, presenting a viable alternative for patients who cannot afford conventional treatments. This research was presented at the annual meeting of the American Society of Clinical Oncology, underscoring the potential for innovative approaches to expand treatment options for underserved populations.
As immune checkpoint inhibitors continue to revolutionize cancer care in wealthier nations, this study emphasizes the importance of adapting these therapies to meet the needs of patients in developing countries, where cancer incidence is rising and treatment options remain limited.
Sources
1 of 1 linked articles